Whole-body MRI may serve as a valuable noninvasive tool for assessing the risk of heart attack and stroke in diabetic patients, according to a new study published online in the journal Radiology. Diabetes is a metabolic disease characterized by an increased concentration of glucose in the blood.
The famed Framingham Heart Study lost 40% of its budget to sequestration, which means layoffs and closures are on the way for the nation's longest-running cardiovascular disease trial. The study lost $4 million of its annual $9 million budget thanks to automatic funding cuts that took effect amid federal sequestration...
European Launch of New Version of Codman Neuro’s Revive SE Thrombectomy Device for Treatment of Acute Ischemic StrokeSeptember 9, 2013 2:06 pm | by Codman Neuro | News | Comments
Codman Neuro, part of DePuy Synthes Companies of Johnson & Johnson, announced the European launch of the REVIVE™ SE Thrombectomy Device, a next generation clot removal device offering enhanced navigation through the cerebral vasculature and rapid restoration of blood flow to the brain after an ischemic stroke.
Once-rejected CardioMEMs will get another shot at FDA approval for its Champion implantable heart failure monitoring systems when the agency's Circulatory System Devices Panel convenes next month, according to a notice in the Federal Register.
A team of scientists at Karolinska Institutet and Harvard University has taken a major step towards treatment for heart attack, by instructing the injured heart in mice to heal by expressing a factor that triggers cardiovascular regeneration driven by native heart stem cells.
Intelomed, Inc., a developer of noninvasive medical devices and technology for monitoring cardiovascular stability, today announced it has secured $4 million in funding from new and existing shareholders through the sale of its Series A-1 Common Preferred stock.
Keystone Heart, a leader in the development of cerebral protection devices for interventional cardiology and cardiac surgery procedures, announced today that its TriGuardT Cerebral Protection Device has received CE Marking, enabling the company to commercially market the TriGuard in Europe and other territories.
Meeting Announcement: October 8-9, 2013 Circulatory System Devices Panel of the Medical Devices Advisory CommitteeSeptember 9, 2013 12:00 am | by U.S. Food & Drug Administration | News | Comments
On both days the committee will discuss, make recommendations, and vote on devices indicated for use in patients with heart failure (HF). On October 8, 2013, the committee will discuss, make recommendations, and vote on information related to the premarket approval application regarding the expansion of indications supported by the BLOCK HF trial...
A slow heart rhythm puts patients at risk of early death, but a cardiac implant may help reset those odds, according to a Dutch study presented this week at the European Society of Cardiology Congress in Amsterdam. A study of pacemakers in 23 Dutch hospitals found that devices implanted to treat slow heart rhythm helped restore normal life expectancy.
Pure cardiac muscle cells, ready to transplant into a patient affected by heart disease. That’s a goal for many cardiology researchers working with stem cells. Having a pure population of cardiac muscle cells is essential for avoiding tumor formation after transplantation, but has been technically challenging.
Four patients in Kuala Lumpur, Malaysia were successfully treated with CardioKinetix's catheter-based Parachute ventricular partitioning device, the Menlo Park, Calif.-based firm announced late last month. The Parachute device is a minimally invasive catheter-based treatment which separates damaged heart muscle from healthy tissue...
Abbott announced today promising preliminary results from a study presented at the ESC Congress 2013, suggesting that its high sensitive troponin test may help doctors improve the diagnosis and prognosis of patients presenting with symptoms of a heart attack.
A University of Iowa physiologist has a new technique to measure the stiffness of the aorta, a common risk factor for heart disease. And it can be as simple as measuring the pulse in your finger. The new procedure works by placing an instrument called a transducer on the finger or over the brachial artery...
Durham, N.C.-based Heart Imaging Technologies won a $2.5 million grant from the National Institutes of Health in support of efforts to build a "corelab of the future." HeartIT pioneered the WebPAX system, which the company calls the 1st FDA-approved zero-footprint medical imaging workstation.
Technology giant Philips awarded a 10-year contract for continuous access of its ultrasound devices to the cardiology department at Medical Center Leeuwarden, a teaching hospital in the Netherlands. The Dutch hospital will also receive training services and periodic structural upgrades as part of the deal.
Manny Villafaña, Chairman and Chief Executive Officer of Kips Bay Medical, Inc., a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting surgery (CABG), provided the following business update to Kips Bay shareholders and the financial community.
Massachusetts-based Asahi Kasei subsidiary Zoll Medical landed a Defense Dept. contract worth up to $210 million, providing defibrillators, monitors, warmers and infusers to multiple divisions of the U.S. armed forces. Zoll beat out 29 other bidders for the contract, according to a DoD report.
New data on Medtronic's Symplicity renal denervation system showed the device is safe and effective at 1 and 3 years, the company announced this week. A pair of analyses released during the the European Society of Cardiology Congress in Amsterdam this week showed positive results for the hypertension treatment system.
Students at the Hebrew University Biodesign program develop a handheld device for rapid and safe IV insertion. Biodesign is a multi-disciplinary, team-based approach to medical innovation, created by the Hebrew University of Jerusalem and Hadassah Medical Center in partnership with Stanford University.
A new prototype device for rapid and safe IV insertion reduces pain in hospitalized children. The semi-automatic handheld device, called SAGIV, identifies veins, inserts a needle and withdraws it in a single movement. It was developed by students and clinicians in the Biodesign program of the Hebrew University of Jerusalem and Hadassah Medical Center.
IN-TIME Study Shows Significant Reduction in All-Cause Mortality in ICD and CRT-D Patients With BIOTRONIK Home Monitoring(R)September 1, 2013 5:09 am | by The Associated Press | News | Comments
BIOTRONIK, the leading manufacturer of cardiac devices celebrating its 50th anniversary this year, announced ground-breaking results from the IN-TIME study today at the ESC (European Society of Cardiology) congress. Coordinating investigator of IN-TIME, Professor Gerhard...
A sales rep's visit could be worth as much as $230 per case in surgeons' use of coronary stents, according to a study in the American Heart Journal. The presence of a company sales rep in the cath lab increased the likelihood that surgeons would opt for drug-eluting over bare-metal stents, researchers said.
When a beating heart slips into an irregular, life-threatening rhythm, the treatment is well known: deliver a burst of electric current from a pacemaker or defibrillator. But because the electricity itself can cause pain, tissue damage and other serious side-effects, a Johns Hopkins-led research team wants to replace these jolts with a kinder, gentler remedy: light.
St. Jude Medical, Inc., a global medical device company, today announced the CE Mark approval of its next-generation EnligHTN Renal Denervation System for treating patients with drug-resistant, uncontrolled hypertension. The system features an advanced generator that delivers simultaneous ablations via a multi-electrode catheter...
The National Institutes of Health (NIH) has awarded a five-year, $1.94 million grant to a biomedical research team at Worcester Polytechnic Institute (WPI) working at the forefront of cell therapies for healing cardiac muscle damaged by heart attack or chronic disease.